DB:RFS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Resverlogix Corp. operates as a late-stage clinical biotechnology company. More Details


Snowflake Analysis

Slightly overvalued with questionable track record.

Share Price & News

How has Resverlogix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RFS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

13.8%

RFS

-5.6%

DE Biotechs

-1.8%

DE Market


1 Year Return

-22.1%

RFS

-4.2%

DE Biotechs

1.7%

DE Market

Return vs Industry: RFS underperformed the German Biotechs industry which returned 1.1% over the past year.

Return vs Market: RFS underperformed the German Market which returned 2.6% over the past year.


Shareholder returns

RFSIndustryMarket
7 Day13.8%-5.6%-1.8%
30 Day26.5%-14.2%-1.6%
90 Day53.5%-14.1%-1.8%
1 Year-22.1%-22.1%-4.1%-4.2%4.9%1.7%
3 Year-20.2%-20.2%-0.7%-1.6%2.0%-6.9%
5 Year-33.9%-33.9%46.7%44.2%24.2%6.5%

Price Volatility Vs. Market

How volatile is Resverlogix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Resverlogix undervalued compared to its fair value and its price relative to the market?

1.76x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RFS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RFS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RFS is good value based on its PE Ratio (1.8x) compared to the XE Biotechs industry average (35.3x).

PE vs Market: RFS is good value based on its PE Ratio (1.8x) compared to the German market (22.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RFS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RFS has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is Resverlogix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

45.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resverlogix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Resverlogix performed over the past 5 years?

14.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RFS has a large one-off gain of $93.0M impacting its July 31 2020 financial results.

Growing Profit Margin: RFS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RFS has become profitable over the past 5 years, growing earnings by 14.9% per year.

Accelerating Growth: RFS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RFS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: RFS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Resverlogix's financial position?


Financial Position Analysis

Short Term Liabilities: RFS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RFS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RFS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RFS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: RFS's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if RFS's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Resverlogix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RFS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RFS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RFS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RFS's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.4yrs

Average management tenure


CEO

Don McCaffrey

17.5yrs

Tenure

US$1,954,165

Compensation

Mr. Donald J. McCaffrey, also known as Don, is a Co-Founder of Resverlogix Corporation and has been its Chief Executive Officer, President since April 25, 2003 and has also been its Chairman of the Board s ...


CEO Compensation Analysis

Compensation vs Market: Don's total compensation ($USD1.11M) is above average for companies of similar size in the German market ($USD702.09K).

Compensation vs Earnings: Don's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Donald McCaffrey
Co-Founder17.5yrsUS$1.95m2.15%
$ 3.6m
Aaron Cann
Chief Financial Officer11yrsUS$745.34k0.070%
$ 116.6k
Kenneth Lebioda
Senior Vice President of Business & Corporate Development15.75yrsUS$693.46k0.070%
$ 116.7k
Michael Sweeney
Senior Vice President of Clinical Development5.92yrsUS$1.37m0.056%
$ 92.0k
Ewelina Kulikowski
Senior Vice President of Research & Development4.5yrsUS$635.03k0.020%
$ 32.9k
Norman Wong
Co-Founder7.5yrsno data1.42%
$ 2.3m
Paul Moon
Vice President of Investor Relations & Communicationsno datano datano data
Sarah Zapotichny
Director of Investor Relations & Corporate Communicationsno datano datano data
Jan Johansson
Senior Vice President of Medical Affairs16.58yrsUS$306.46k0.054%
$ 89.2k

13.4yrs

Average Tenure

Experienced Management: RFS's management team is seasoned and experienced (13.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Donald McCaffrey
Co-Founder17.5yrsUS$1.95m2.15%
$ 3.6m
Norman Wong
Co-Founder7.5yrsno data1.42%
$ 2.3m
Kenneth Zuerblis
Independent Director10.08yrsUS$359.79k0.049%
$ 81.4k
Jeffrey Cummings
Member of Neurodegenerative Clinical & Scientific Advisory Board8.25yrsno datano data
Kelly McNeill
Independent Director11yrsUS$355.41k0.048%
$ 79.8k
Bengt Winblad
Chairman of Neurodegenerative Clinical & Scientific Advisory Board8.25yrsno datano data
Norma Biln
Lead Independent Directorno dataUS$372.89k0.027%
$ 45.2k
Henrik Zetterberg
Member of Neurodegenerative Clinical & Scientific Advisory Board8.25yrsno datano data
Radosveta Koldamova
Member of Neurodegenerative Clinical & Scientific Advisory Board8.25yrsno datano data
Shawn Lu
Director4.5yrsUS$278.87kno data
Kamyar Kalantar-Zadeh
Chairman of Renal Clinical Advisory Boardno datano datano data
Srinivasan Beddhu
Member of Renal Clinical Advisory Boardno datano datano data

8.3yrs

Average Tenure

61yo

Average Age

Experienced Board: RFS's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Resverlogix Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Resverlogix Corp.
  • Ticker: RFS
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$257.054m
  • Listing Market Cap: CA$165.574m
  • Shares outstanding: 217.84m
  • Website: https://www.resverlogix.com

Number of Employees


Location

  • Resverlogix Corp.
  • 4820 Richard Road SW
  • Suite 300
  • Calgary
  • Alberta
  • T3E 6L1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RVXTSX (The Toronto Stock Exchange)YesCommon SharesCACADApr 2003
RFSDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2003
RVXC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2003
0VF9LSE (London Stock Exchange)YesCommon SharesGBCADApr 2003

Biography

Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Ph ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 21:17
End of Day Share Price2020/10/20 00:00
Earnings2020/07/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.